As of 2024-12-12, the EV/EBITDA ratio of 4D Molecular Therapeutics Inc (FDMT) is -0.55. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FDMT's latest enterprise value is 131.45 mil USD. FDMT's TTM EBITDA according to its financial statements is -240.17 mil USD. Dividing these 2 quantities gives us the above FDMT EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.4x | 16.0x |
| Forward P/E multiples | 19.5x - 28.7x | 25.1x |
| Fair Price | (72.52) - 5.56 | (36.85) |
| Upside | -1151.0% - -19.4% | -634.0% |
| Date | EV/EBITDA |
| 2024-12-04 | -0.59 |
| 2024-12-03 | -0.58 |
| 2024-12-02 | -0.68 |
| 2024-11-29 | -0.73 |
| 2024-11-27 | -0.73 |
| 2024-11-26 | -0.66 |
| 2024-11-25 | -0.69 |
| 2024-11-22 | -0.72 |
| 2024-11-21 | -0.76 |
| 2024-11-20 | -0.84 |
| 2024-11-19 | -0.89 |
| 2024-11-18 | -0.82 |
| 2024-11-15 | -0.92 |
| 2024-11-14 | -0.76 |
| 2024-11-13 | -0.70 |
| 2024-11-12 | -0.73 |
| 2024-11-11 | -0.77 |
| 2024-11-08 | -0.78 |
| 2024-11-07 | -0.81 |
| 2024-11-06 | -0.83 |
| 2024-11-05 | -0.83 |
| 2024-11-04 | -0.79 |
| 2024-11-01 | -0.78 |
| 2024-10-31 | -0.76 |
| 2024-10-30 | -0.81 |
| 2024-10-29 | -0.80 |
| 2024-10-28 | -0.87 |
| 2024-10-25 | -0.79 |
| 2024-10-24 | -0.80 |
| 2024-10-23 | -0.86 |
| 2024-10-22 | -0.81 |
| 2024-10-21 | -0.87 |
| 2024-10-18 | -0.86 |
| 2024-10-17 | -0.85 |
| 2024-10-16 | -0.89 |
| 2024-10-15 | -0.93 |
| 2024-10-14 | -0.96 |
| 2024-10-11 | -0.98 |
| 2024-10-10 | -0.90 |
| 2024-10-09 | -0.95 |
| 2024-10-08 | -1.02 |
| 2024-10-07 | -1.00 |
| 2024-10-04 | -1.14 |
| 2024-10-03 | -1.21 |
| 2024-10-02 | -1.20 |
| 2024-10-01 | -1.22 |
| 2024-09-30 | -1.30 |
| 2024-09-27 | -1.30 |
| 2024-09-26 | -1.33 |
| 2024-09-25 | -1.39 |